|Bid||1.4400 x 3200|
|Ask||1.4600 x 3000|
|Day's Range||1.3800 - 1.4900|
|52 Week Range||0.5250 - 3.3900|
|Beta (5Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.